A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas

This is a non-randomized, open-label, investigator-initiated phase II clinical trial designed to evaluate the efficacy and safety of sacituzumab tirumotecan (hereafter referred to as sac-TMT) in patients with unresectable thymic carcinoma who have a history of platinum-based combination chemotherapy.

NCT Number	NCT07750353
Lead Sponsor	National Cancer Center, Japan
Conditions	Unresectable Thymic Carcinoma
Enrollment	35 participants
Start Date	2027-02-01
Primary Completion	2029-12 (estimated)
Study Completion	2030-06 (estimated)
Updated on ClinicalTrials.gov	2026-08-06